Introduction {#sec1}
============

CD200 (formerly termed OX2) is a widely distributed cell surface protein that interacts with a receptor (CD200R) that is highly expressed on myeloid and some lymphoid cells ([@bib45], [@bib47]). CD200R contains tyrosine motifs that can be phosphorylated. These motifs signal through the recruitment of the adaptor DOK2, which distinguishes CD200R from almost all other inhibitory receptors, that contains immunoreceptor tyrosine-based inhibition (ITIM) motifs that provide inhibition following recruitment of phosphatases ([@bib34]; [@bib48]). The broad tissue distribution of CD200 and changes in its level of expression provide a mechanism for locally regulating myeloid cell activity at appropriate sites, such as inflamed tissue ([@bib8]; [@bib37]; [@bib38]). The gene for CD200 has been acquired by several viruses and in some cases has been shown to cause downregulation of myeloid activity ([@bib19], [@bib20]; [@bib39]; [@bib49]). The CD200/CD200R homeostatic mechanism is of major interest as a target for immunomodulation both to reduce myeloid activity in inflammatory conditions and to block inhibitory signals provided by cancer cells. Inflammation is ameliorated by cross-linking the receptor with CD200-Fc fusion proteins in models of arthritis and allograft rejection ([@bib21], [@bib22]) or by antibodies in virus-induced cytokine storm ([@bib40]). High levels of CD200 have been associated with poor prognosis in certain cancers, suggesting that CD200 may be protecting the tumor by inhibiting myeloid cells through CD200R, and CD200 mAb are being tested to restore myeloid cell activity and help eliminate tumor cells ([@bib27]; [@bib36]; [@bib42]). The CD200/CD200R interaction has similarities with the CD47 interaction with the SIRP paired receptor family in that both ligands are widely distributed but receptors are restricted mainly to myeloid cells and both CD200 and CD47 are targets for leukemia therapy ([@bib12]; [@bib26]). However the inhibitory SIRPα is a conventional inhibitory receptor using ITIM motifs recruiting phosphatases ([@bib6]).

Both CD200 and CD200R contain two Ig-like domains and a single-pass transmembrane region. They are heavily glycosylated with six potential N-linked sites in CD200 and typically six to ten in CD200R according to species ([@bib5]; [@bib31]; [@bib45], [@bib47]). CD200R is a member of a "paired receptor" family as in addition to this inhibitory receptor there is one very closely related gene with activating potential in humans and several in mice ([@bib1]; [@bib47]). These were termed CD200RL for receptor-like but have also been termed CD200R1, CD200R2, etc. ([@bib23]; [@bib43]). What is intriguing about several paired receptors is that their extracellular regions typically have about 90% amino acid sequence identity but there is a major difference in ligand binding between the activating and inhibitory members. The activating CD200RL proteins give negligible binding to CD200 so that the change of function from inhibitory to activatory is associated with a loss of ability to interact with host ligand ([@bib25]). One theory is that this evolution is being driven by pathogens targeting the inhibitory receptor ([@bib2]; [@bib7]). The interaction between CD200 and CD200R involves their NH~2~ terminal domains and hence is predicted to span about four Ig-like domains typical of interactions in immunological synapses ([Figure 1](#fig1){ref-type="fig"}). Because CD200 is expressed on nonlymphoid cells as well as leukocytes, it seems likely that synapse-like interactions may be widely utilized ([@bib45]).

We describe the X-ray crystallographic analysis of the extracellular regions of the mouse CD200R, one of the activating receptors, CD200RLa, and a complex between CD200R and its ligand CD200. We discuss the implications for paired receptor specificity, the evolution of these receptors and pathogen pressure, and the implications of the topology of the interaction in constraining the engagement of the receptor.

Results and Discussion {#sec2}
======================

Production of Recombinant Proteins for X-ray Crystallographic Analysis {#sec2.1}
----------------------------------------------------------------------

To provide homogenous protein for X-ray crystallography, the extracellular regions consisting of two Ig-like domains of CD200, CD200R, and CD200R-like proteins were expressed in CHO cells that were defective in glycosylation so that the N-linked glycosylation sites did not mature beyond the high mannose state ([@bib15]; [@bib41]), making it possible to obtain more homogenous protein by endoglycosidase H treatment. Glycoforms of CD200 and CD200R resistant to endoglycosidase H were removed by passing the recombinant proteins through a concanavalin A affinity column that preferentially binds high mannose structures, allowing recombinant protein deglycosylated back to N-acetyl-glucosamine (NAG) to pass through the column ([Figure S1](#app3){ref-type="sec"} available online).

Crystallization and Structure Determination {#sec2.2}
-------------------------------------------

Crystals were obtained for the extracellular regions of CD200RLa, CD200R alone, and CD200R in complex with CD200 and native diffraction data were recorded to 2.6, 2.1, and 3.2 Å, respectively ([Table 1](#tbl1){ref-type="table"}). The structure of CD200RLa was solved after phase determination using crystals soaked in gadolinium chloride solution because molecular replacement (MR) phasing was unsuccessful. The structure of CD200R was solved by molecular replacement using the coordinates of CD200RLa as a search model ([Figure 2](#fig2){ref-type="fig"}). The coordinates of CD200R were used as a MR search model for the CD200R/CD200 complex and CD200 was built in a map calculated using partial MR phases. Details of the crystallographic data collection and refinement are given in [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}, and the structures are given in [Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}.

Structural Characteristics of CD200R and CD200RLa {#sec2.3}
-------------------------------------------------

CD200R and CD200RLa contain typical Ig-like domains consisting of an NH~2~-terminal V-like domain followed by a smaller C2-like domain. In both molecules, the A strand of the V-like domain is on the extensive GFCC′C″ face as is commonly found in Ig-like domains ([@bib4]) and there is a short alpha helix in the EF loop of the V-like domain. NH~2~-terminal amino acid sequencing confirmed the presence of an usually long NH~2~-terminal region prior to the predicted beginning of the IgSF V-like domains of CD200R and CD200RLa ([Figure 4](#fig4){ref-type="fig"}). The first NH~2~-terminal residue for which electron density was observed is P15 in CD200R and Q18 for CD200RLa. The absence of electron density for the potentially glycosylated NH~2~-terminal region suggests this region is flexible and able to adopt different conformations.

The structure of CD200RLa is very similar to that of CD200R, as expected due to their high amino acid sequence identity in their extracellular regions (86%). There are significant differences in the loops (BC, CC′, and DE) of the V-like domain, but this is probably a consequence of their involvement in forming crystal contacts in the CD200R crystal. Superposition of the V-like domains of CD200R and CD200RLa reflects these differences with an average root mean square deviation (rmsd) of 2.05 Å over 106 Cα atoms whereas the C2-like domains superimpose with an rmsd of 0.6 Å over 80 Cα atoms.

Both CD200R and the CD200RLa contain disulfide bonds in addition to the canonical disulfide of most Ig-like domains that links beta strands B and F in each domain, which are largely conserved in mammals. Intrasheet disulfides are found between beta strand C′ and the C″D loop in the V-like domain and between beta strands D and E in the C2-like domain. Interestingly, the V-like domains of CD200R and CD200RLa have an exposed Cys (C34) at the end of beta strand B to which a short portion of continuous electron density was observed, and in which a Cys (forming a disulfide bond with C34) was modeled ([Figure S2](#app3){ref-type="sec"}). This extra density was observed in the structures of CD200R alone, CD200R in complex with CD200, and in all three independent molecules of CD200RLa present in the asymmetric unit. Because the crystallization conditions differ for each protein, it is unlikely that the free Cys was modified by a component of the crystallization solution. Presumably CD200R and CD200RLa picked up Cys from the CHO cell medium during expression. The roles of most of these extra disulfides are presumably structural; however, other functional roles cannot be excluded ([@bib33]).

Structural Characteristics of CD200 {#sec2.4}
-----------------------------------

The structure of CD200 was solved in complex with CD200R and contains an NH~2~-terminal Ig V-like domain followed by a smaller C2-like domain ([Figure 3](#fig3){ref-type="fig"}). The topology is very similar to that of CD200R including the short alpha helix in the EF loop. The CD200 C2-like domain is characterized by extremely high B factors (130Å^2^) despite packing against another CD200 molecule. In addition to a disulfide bond between beta strands B and F in both IgSF domains of CD200, there is an exposed disulfide bond between beta strands F and G in the V-like domain. This disulfide bond is conserved in CD200 orthologs (including viral ones discussed subsequently), but disulfides in this position are unusual in Ig-like domains. NAG moieties were modeled at all six of the N-linked glycosylation sites (N65, N73, N80, N127, N151, and N160) of CD200.

Structure of the CD200/CD200R Complex {#sec2.5}
-------------------------------------

The structure of the CD200/CD200R complex shows near orthogonal binding of the V-like domains of each molecule, whereby the CD200 FCC′C″ face and CC′ and FG loops form a concave surface that embraces the relatively flat AGFCC′C″ face and FG loop of CD200R ([Figures 3](#fig3){ref-type="fig"}A and [3](#fig3){ref-type="fig"}B). Five NAG moieties were modeled for the bound CD200R at the same Asn as NAGs were modeled for CD200RLa. Despite the high content of carbohydrate in both CD200 and CD200R, it is not involved in the interaction, with N-linked glycosylation of both CD200 and CD200R distant from the interface with the exception of N20 of CD200R, which lies at the periphery of the interaction interface. The CD200/CD200R interaction buries a total of 1768 Å^2^ of solvent-accessible area (901 Å^2^ from CD200 and 868 Å^2^ from CD200R) and shows high shape complementarity with a shape correlation score (SC) of 0.69. The interaction interface also shows charge complementarity with acidic patches on CD200R complementing basic patches on CD200 ([Figures 3](#fig3){ref-type="fig"}C and 3D) where a network of polar interactions is clustered. Hydrogen bonds are formed between residues (including water-mediated hydrogen bonds) in the CD200R AGFCC′ beta strands (T17, E115, F114, N113, E106, T47, T59), FG loop (P110, E111, N113) and the CD200 FCC′ beta strands (T33, Q35, N44, T47, N94), and CC′ (S41, P42), C''D (Q57) and the FG loops (T95, G97, S98, Q99, K100). There are two salt bridges with K100 (FG loop) of CD200-forming salt bridges with E106 (beta strand F) and E115 (beta strand G) of CD200R. Hydrophobic interactions are mediated between residues across the top of the FCC′C″ face of CD200R and residues in the C strand and FG loop of CD200. In particular F96 (in the FG loop) of CD200 mediates numerous hydrophobic interactions where the phenyl ring sits in a hydrophobic pocket formed by residues in the CD200R CC′C″ beta sheet (L45, A61, Y62, K63, T68, N69, and E70).

Superposition of the V-like domains (residues 17--126) of CD200R alone and in complex with CD200 supports the earlier suggestion that the NH~2~-terminal region of CD200R is flexible; a rotation of the main chain around residue 17 results in residues 15-16 moving from the front GFC face (which would impede binding to CD200) to the back BED face, exposing the CD200 binding face ([Figure S3](#app3){ref-type="sec"}). Other than the NH~2~ terminus, there are no significant changes to the interacting face of CD200R upon binding. Conformational differences between the bound and unbound CD200R are seen in the BC loop (residues 37--41), DE loop (residues 82--87), and to a lesser extent in the EF loop (residues 93--94). These loops are not involved in the interaction with CD200, and these differences are due to the different packing of the molecules within the crystals and also reflect the plasticity of these loops.

Validation of the CD200/CD200R Interface {#sec2.6}
----------------------------------------

While some key residues in the CD200/CD200R interaction had been identified in CD200R previously by mutagenesis there were few data for CD200. Single point mutants of mouse CD200 containing a CD4 tag at the COOH terminus were expressed in 293T cells and immobilized onto a BIAcore 3000 CM5 chip precoated with a CD4 mAb. The ability of each CD200 mutant to bind CD200R was assessed by passing over soluble CD200R at 0.5 μM (the K~D~ of the interaction at 25°C) and comparing the binding responses with wild-type CD200. A typical BIAcore experiment is shown in [Figure 5](#fig5){ref-type="fig"}A for wild-type CD200, mutant CD200 proteins Q7K and N44A, and a negative control protein CD4 (domains three and four). N44 of CD200 is in beta strand C′, mediating hydrogen bonding with N113 of CD200R, and mutation of N44 to alanine destroys this interaction ([Figure 5](#fig5){ref-type="fig"}A). Residue 7 (Q7) of CD200 is not involved in the interaction with CD200R and is located in beta strand A; hence mutation of this residue to lysine (Q7K) did not affect binding to CD200R. Mutation of other CD200 residues (L30, I31, L92, N94, and F96) at the CD200R binding interface also effectively destroyed ligand binding by disrupting either polar or hydrophobic interactions whereas mutations of residues outside the binding interface retained binding ability ([Figure 5](#fig5){ref-type="fig"}B; [Table S1](#app3){ref-type="sec"}). CD200 mutant Q27K gave 150% wild-type binding response. Although Q27 does not make contact with CD200R, it is at the periphery of the interface and mutation to lysine may allow salt bridge formation with E70 of CD200R. All mutants were expressed well and reacted with the CD200 mAb OX90, which recognizes a conformationally sensitive epitope (unpublished observations).

The ligand binding domains of mouse and human CD200R share 51% amino acid sequence identity (residues 1--123; [Figure 4](#fig4){ref-type="fig"}) and human CD200 binds to mouse CD200R with a similar affinity as mouse CD200 (K~D~s of 7 and 4 μM at 37°C, respectively) ([@bib19]; [@bib25]). Hence the interaction is likely to be similar for both species allowing data from a previous mutagenesis study of the human proteins ([@bib24]) to be mapped onto the mouse CD200/CD200R complex. All mutated residues in human CD200R that gave less than 25% binding to CD200 as compared to wild-type protein are located at the mouse CD200/CD200R interaction interface ([Figure 5](#fig5){ref-type="fig"}C) and mutations that had an intermediate effect (25%--75%) are at the periphery of the interaction interface.

Why Doesn't Mouse CD200RLa Bind CD200? {#sec2.7}
--------------------------------------

Despite CD200RLa sharing a high amino acid sequence identity with CD200R in the V-like domain (84% identity in residues 1--123), it gives minimal binding to CD200 (50-fold lower affinity; [@bib47]). Comparison of the CD200R and CD200RLa sequences does not show simple changes in the contact residues that might explain why the activating receptor CD200RLa does not bind CD200, implying indirect effects. To investigate this, the structure of the V-like domain of CD200RLa was superimposed onto CD200R in complex with CD200. CD200RLa and CD200R differ by 20 amino acids in the V-like domain but genome analysis shows that three of these are found as natural variants in CD200R, indicating 17 definitive differences. The first four differences between the two molecules are in the NH~2~-terminal region (residues 1--15), which is not seen in the structure of CD200RLa. Many of the amino acid differences are distant or peripheral (residues 23, 28, 29, 38, 41, 42, 52, 54, and 117) to the interface ([Figure 6](#fig6){ref-type="fig"}A). Residues 63 and 66 in the C′C″ loop differ between CD200R and CD200RLa and are at the periphery of the interaction with K63, making contact with F96 and L30 of CD200. Although residue 66 is not directly involved in the interaction, a difference at this position may adversely affect positioning of residue 63. Single point mutation of either residues 63 or 66 of CD200RLa to the equivalent residue in CD200R (N63K and K66T, respectively) does not result in CD200 binding. However the CD200RLa double mutant N63K K66T does bind CD200, although with an affinity (K~D~ = 18.4 μM) about 30 times weaker than that with CD200R ([Figure 6](#fig6){ref-type="fig"}B). Residue 114 in beta strand G is Phe in CD200R and makes contact with N44 of CD200. However, it also stacks against F36 in CD200R and together these stacked aromatic residues are involved in hydrophobic interactions with the NH~2~-terminal strand of CD200R, helping to stabilize the CD200 binding conformation of residues 15--20 of CD200R ([Figure 6](#fig6){ref-type="fig"}B). Substitution of F114 for Leu in CD200RLa seems to cause the side chain of F36 to flip in the opposite direction into the core of the domain. This in turn leads to the destabilization of the NH~2~ region of CD200RLa and therefore disruption of the CD200 binding interface ([Figure 6](#fig6){ref-type="fig"}B). Mutation of L114 of CD200RLa to Phe (L114F) results in binding to CD200 with a K~D~ of 4.2 μM, about seven times weaker than the CD200/CD200R interaction ([Figure 6](#fig6){ref-type="fig"}C). Thus both regions are important in explaining why the CD200RLa does not bind CD200 and this argument was strengthened by the analysis of a CD200RLa triple mutant combining both regions (N63K, K66T, and L114F) that binds CD200 with a similar affinity as CD200R ([Figure 6](#fig6){ref-type="fig"}C).

The three residues that are critical for CD200RLa not binding CD200 are not conserved in the other activating receptors, indicating that these fail to bind CD200 for different reasons ([Figure S4](#app3){ref-type="sec"}). This resembles the situation seen in the SIRP family, where two activating alleles of SIRPβ use different mechanisms not to bind ligand ([@bib26]). In addition, the CD200RLb differs greatly from the other activating receptors with only 32% amino acid identity with CD200R in the V-like domain (residues 1--124) and many residues could be important in its failure to bind CD200.

Topology of the CD200/CD200R Interaction {#sec2.8}
----------------------------------------

The structure of the CD200/CD200R complex allows the topology of the interaction between two opposing cells to be modeled. The distance between the last residues of each molecule in the structural model is ∼12 nm; this appears somewhat smaller than the 14 nm typically found for protein interactions spanning the immunological synapse; however, a further nine residues of CD200R need to be accounted for before entering the predicted transmembrane region. Allowing for these linking residues suggests that the distance spanned between two opposing cells is likely to be similar to other well-characterized interactions involved in fine tuning of the immune response such as those found in the T cell immunologic synapse ([Figure 7](#fig7){ref-type="fig"}). As this interaction occurs between mostly myeloid cells and a variety of other cell types including epithelial cells, the topology indicated supports a previous proposal ([@bib45]) that synapse-like interactions may be found in a variety of cell types and more specifically to regulate myeloid cell function (such as CD200/CD200R and CD47/SIRPα; [Figure 7](#fig7){ref-type="fig"}).

There are many functional data indicating that the CD200/CD200R interaction acts between cells (trans) ([@bib19]; [@bib27]). The possibility that it occurs also in *cis* seems unlikely given the steric constraints from the extensive glycosylation of both proteins, in particular at residues Asn127 and Asn151 of CD200. In addition CD200 is widely expressed compared to CD200R and rarely on the same cells so this is unlikely to be a major factor ([@bib37]; [@bib46]).

Implications of Paired Receptor Function and Evolution {#sec2.9}
------------------------------------------------------

### The CD200/CD200R Interaction and Viral Orthologs {#sec2.9.1}

When the sequences of CD200 and CD200R are compared across species, it is clear that CD200R is evolving more rapidly that CD200 ([Figure 8](#fig8){ref-type="fig"}). Viruses are constantly evolving to subvert the immune system and CD200-like orthologs containing two Ig-like domains have been identified in beta- and gammaherpesviridae ([@bib19]). The human herpesvirus-8 (HHV-8; Kaposi sarcoma virus) CD200 ortholog (K14) mimics the interaction of human CD200 with CD200R to suppress macrophage and T cell responses to virus and K14 binds CD200R with the same affinity as the host CD200 protein ([@bib19]; [@bib35]). The rat cytomegalovirus (RCMV) CD200 ortholog e127 also mimics the host protein in terms of affinity ([@bib20]). Most of the residues in K14 and e127 predicted to be at the CD200R interface are mostly either identical or conservative changes compared to human and rat CD200, respectively, although the overall amino acid sequence identity in the V-like domain is 41% and 87%, respectively ([@bib19]). This is illustrated in [Figure 8](#fig8){ref-type="fig"}, which compares the CD200s from mammals and includes the viral orthologs; it shows there is considerable divergence in domain 2 but less in the binding face in domain 1. It has been suggested that the heterogeneity in the paired receptors is a result of pathogen pressure where pathogens target the inhibitory receptors. These then evolve both by sequence change and by the generation of activating genes that no longer bind the host ligand but may provide decoys for pathogens targeting the inhibitory receptor (the counterbalance theory; [@bib7]). With regard to CD200/CD200R, the viral orthologs of CD200 may not be the driving force for the evolution of these activating receptors because they mimic the host CD200 so closely as indicated by their similar affinities. Thus the evolution of the CD200R family may have been driven by as yet unidentified pathogens.

Conclusions {#sec2.10}
-----------

The structures indicate that CD200 and CD200R consist of two typical Ig-like domains interacting though their NH~2~-terminal domains so that the interaction has dimensions compatible with functioning in an immunological synapse. What is unusual about this interaction is that CD200 is expressed widely on endothelial and epithelial cells, suggesting that immunological style synapses may be important in these types of interactions in addition to the well-characterized interactions between leukocytes. Restricting the interaction to synapse-like regions may limit the conditions in which the receptor gets phosphorylated and may restrict access to pathogens targeting this receptor as suggested for the CD47/SIRPα interaction ([@bib7]; [@bib26]). This interaction has many similarities to the CD200/CD200R interaction whereby a widely distributed ligand (CD47) reacts with a receptor restricted to myeloid cells (SIRPα) and the interaction is also a target for enhancing immunity to cancer ([@bib12]).

One feature of CD200R is its extensive glycosylation (eight to ten N-linked sites depending on species) and that this glycosylation is distant from the interacting faces ([Figure 3](#fig3){ref-type="fig"}A). It is possible that this prevents unwanted interactions that might occur during the rapid evolution of the receptor and indeed this may be a common role for glycosylation of many leukocyte receptors that are generally evolving fast compared to those of other cell types ([@bib4]).

The finding that subtle changes around the binding site are responsible for the failure of the activating receptors to bind CD200 is reminiscent of other paired receptors such as the SIRPs ([@bib26]). This suggested that the activating receptor has evolved from the inhibitory receptor and specifically to not bind host ligand. In this way it provides a defense mechanism for pathogens that are targeting the inhibitory receptors (discussed in [@bib7]). The finding that many virus types have acquired CD200 orthologs supports this concept. In some viruses (e.g., HHV8 and rCMV), the CD200 ortholog acts as a close mimic in terms of binding. Thus the structures provide evidence for a paired receptor system involved in homeostasis that is evolving rapidly under pathogen pressure. Given the importance of myeloid cells and their expression of CD200R, it seems likely that interactions with the microbiome may well be reflected in setting the levels of immune responses ([@bib2]). The presence of polymorphisms and heterogeneity in the repertoire of the CD200 paired receptor system may be important in disease susceptibility.

Experimental Procedures {#sec3}
=======================

Expression and Production of Recombinant Proteins for Crystallization {#sec3.1}
---------------------------------------------------------------------

Recombinant mouse CD200RLa comprising the leader sequence, the two extracellular IgSF domains (residues 1--237, accession number [NP_997127](ncbi-p:NP_997127){#intref0010}) followed by a C-terminal polyhistidine tag (STRHHHHHH) was expressed using the pEE14 vector in the CHO Lec3.2.8.1 cell line. The extracellular regions of mouse CD200R (residues 1--232; accession number [NP_067300](ncbi-p:NP_067300){#intref0015}) and mouse CD200 (residues 1--232; accession number [NP_034948](ncbi-p:NP_034948){#intref0020}) were also expressed with a C-terminal polyhistidine tag in the same manner as mouse CD200RLa.

The recombinant proteins were purified by nickel affinity chromatography and buffer exchanged into 10 mM HEPES pH 7.5, 150 mM NaCl, 0.02% NaN~3~ (HBS). N-linked sugars were removed using 2.5 U of Endoglycosidase Hf (NEB) per microgram of protein. Recombinant CD200R and CD200 were further purified by passing through a concanavalin A (Con A) Sepharose 4B column (GE Lifesciences), collecting the protein in the flow-through. Recombinant CD200 and CD200R eluted from the concanavalin A column were used as ligands in mutagenesis experiments (see subsequent section). All recombinant proteins were gel-filtrated into HBS buffer to remove contaminants and aggregated protein.

NH~2~-terminal protein sequences were determined using an automated Edman degradation in an Applied Biosystems Procise 494A protein sequencer (Perkin-Elmer Ltd, UK).

Crystallization {#sec3.2}
---------------

Sitting drop vapor diffusion crystallization experiments were performed using an OryxNano robot (Douglas Instruments) to dispense nanoscale protein-precipitant drops that were equilibrated against precipitant reservoirs at either 12°C or 20°C. CD200RLa was concentrated to 9.6 mg/ml and P6~5~22 crystals grew (within 24 hr) from 300 nl drops containing 50% and 66% protein from 0.2 M sodium chloride, 0.1 M sodium cacodylate pH 6.5, and 2.0 M ammonium sulfate at 12°C. Crystals were cryoprotected in mother liquor supplemented with 20% glycerol and flash frozen in liquid nitrogen.

P4~1~2~1~2 crystals of CD200R grew from drops containing a 1:1 molar mix of CD200 and CD200R (each protein at 320 μM). Crystals grew (within 2 weeks) from 400 nl drops containing 50% and 70% protein from 0.2 M ammonium acetate, 0.1 M sodium acetate pH 4.0, 15% w/v PEG 4000 at 20°C. The CD200R crystal was cryoprotected in mother liquor supplemented with 20% glycerol and flash frozen in liquid nitrogen.

For the CD200/CD200R complex (each protein at 350 μM), crystals grew at 20°C from a 400 nl drop containing 70% protein from 1.0 M imidazole pH 7.0 and were cryoprotected in mother liquor containing 35% ethylene glycol and flash frozen in liquid nitrogen.

Data Processing and Structure Determination {#sec3.3}
-------------------------------------------

A native X-ray diffraction data set for mouse CD200RLa was collected at the European Synchrotron Radiation Facility (ESRF, Grenoble) at a wavelength of 0.9762 Å and was processed using Mosflm ([@bib30]) and SCALA ([@bib18]). To obtain heavy metal derivatives, CD200RLa crystals were soaked in 65 mM gadolinium chloride for 2 minutes, cryoprotected in mother liquor containing 20% glycerol, and flash frozen in liquid nitrogen. A gadolinium derivative diffraction data set was collected at the Diamond Light Source (UK) at 1.7112 Å (the LIII absorption edge). Derivative data were processed using the Xia2 data processing suite ([@bib44]). The autoSHARP suite of programs ([@bib16]) was used to generate initial phases in a single isomorphous replacement with anomalous signal (SIRAS) experiment using the native and derivative data sets. SHELX D found six gadolinium sites and SHARP refined the coordinates, occupancy, and B factors for these sites and generated residual maps and phases. Solvent flattening was performed by SOLOMON to give new phases to 2.5 Å into which 561 residues of mCD200RLa were autobuilt by the Buccaneer program ([@bib14]). Iterative cycles of manual model building in COOT ([@bib17]) and refinement with BUSTER-TNT ([@bib9]) were performed.

Diffraction data for CD200R and the CD200/CD200R complex were collected at Diamond on beamline I04 at 100 K ([Table S1](#app3){ref-type="sec"}). Diffraction data sets were processed using Xia2 ([@bib44]). The structure of CD200R was determined by molecular replacement using Phaser ([@bib32]) with the CD200RLa structure as a search model. Domains 1 and 2 of CD200RLa were initially used sequentially as molecular replacement search models by Phaser to determine initial phases for CD200R. Buccaneer was used to autobuild followed by iterative cycles of refinement with autoBUSTER ([@bib10]) and manual model building in COOT.

The structure of the CD200/CD200R complex was initially solved by molecular replacement using Phaser with domains 1 and 2 of CD200R. Phases calculated from this partial model using autoBUSTER produced a map with clear density that allowed placement of a canonical immunoglobulin domain (domain 1 from 3ALP). Refinement of this model allowed manual placement of the second domain. Iterative cycles of refinement with autoBUSTER ([@bib10]) and manual model building in COOT produced a complete model for CD200, with the positions of the glycosylated Asn residues verifying the remodeled sequence. Molecular graphics were generated using Pymol (<http://www.pymol.org>; Schrödinger). Electrostatic surface potentials were calculated using the Pymol APBS Tools 2 plugin. The CD200/CD200R structure was analyzed using the protein interfaces, surfaces, and assemblies service PISA at European Bioinformatics Institute (<http://www.ebi.ac.uk/pdbe/prot_int/pistart.html>) ([@bib28]).

CD200 Mutagenesis and Analysis by Surface Plasmon Resonance {#sec3.4}
-----------------------------------------------------------

Surface plasmon resonance experiments were performed using a BIAcore 3000 at 25°C. Recombinant CD200R and CD200 eluted from respective Con A columns (see expression section above) were gel-filtrated in HBS. The extracellular region of CD200 (residues 1--232) was tagged at the C terminus with domains 3 and 4 of rat CD4 (CD4) followed by a biotinylation (Bio) site and transiently expressed by 293T cells as described previously ([@bib11]). Single point mutants of CD200 were generated by overlap extension polymerase chain reaction. OX68 mAb (mouse anti-rat CD4) was amine coupled to a CM5 chip and approximately 650 response units (RUs) of each protein immobilized. Serial dilutions of CD200R were injected over immobilized wild-type and mutant CD200 and CD4 control protein. A k~D~ of 0.5 μM was calculated from equilibrium binding data and this concentration of CD200R was used to test the binding ability of mutant CD200 proteins compared to wild-type protein. A CD200 mAb (OX90) was passed over the proteins at 0.2 mg/ml. The ligand and antibody responses obtained for the control CD4 protein were subtracted from the wild-type and mutant CD200 responses to obtain the specific binding response for each protein. To compensate for any variation in protein levels immobilized on each flow cell the specific binding response for each protein was divided by the amount of protein immobilized and then expressed as a percentage of wild-type protein (100%). The OX68 chip was regenerated by passing over 0.1 M glycine HCl pH 2.0 to remove immobilized proteins.

Similarly, CD200R (residues 1--232) and wild-type and mutant CD200RLa (residues 1--237) CD4-Bio chimeric proteins were expressed and immobilized via OX68 onto a CM5 BIAcore chip. Increasing concentrations of CD200 were injected over the immobilized proteins and K~D~s were obtained by nonlinear curve fitting to the data.

Accession Numbers {#app1}
=================

The atomic coordinates and structure factors for CD200R, CD200RLa, and the CD200R/CD200 complex reported in this paper have been deposited in the Protein Data Bank under ID codes [4bfg](pdb:4bfg){#intref0035}, [4bfe](pdb:4bfe){#intref0040}, and [4bfi](pdb:4bfi){#intref0045}, respectively.

Supplemental Information {#app3}
========================
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![Schematic Illustrating Interactions between an Antigen-Presenting Cell and T Cell\
Immunogloblin domains are shown as ovals. Fibronectin domains are shown as ovals with the letter F inside. Scavenger receptor cysteine-rich domains are shown as rectangles. Tumor necrosis factor receptor (TNFR) and TNF domains are represented by long thin rectangles and long thin ovals, respectively. The mucin-like structure of CD43 and the N-terminal glycosylated region of CD45 are shown as lines.](gr1){#fig1}

![Structural Characteristics of Mouse CD200R.\
The mouse CD200R structure is shown as an orange cartoon. Beta strands of each Ig-like domain are labeled A-G. Observed N-acetylglucosamine (NAG) moieties (N20, N69 and N168) are shown as pink sticks and other potential N-linked glycosylation sites are represented by pink spheres N77, N135, N183 and N197. Disulfide bonds are shown as yellow sticks. Cys 34 is shown forming a disulfide bond with a free Cys (gray stick). CD200R is rotated 180° in right hand panel.\
See also [Figure S2](#app3){ref-type="sec"}.](gr2){#fig2}

![Structure of the CD200/CD200R Complex\
(A) The complex is shown with CD200 in green and CD200R in orange. Beta strands of each Ig-like domain are labeled A--G. Observed NAG moieties are shown as pink sticks and potential N-linked glycosylation sites are represented by pink spheres. Disulfide bonds are represented as yellow sticks.\
(B) Representative electron density showing CD200 (green carbon atoms) and CD200R (orange carbon atoms) at the interaction interface. The final refined model is shown in 2Fo-Fc electron density (1 σ) calculated at the end of refinement.\
(C and D) Open book representation of the CD200 / CD200R interface. The surface of CD200R as viewed by CD200 (C). The molecular surface of CD200R is shown colored by electrostatic potential with the residues at the interaction interface bordered by a black line. The surface of CD200 as viewed by CD200R (D). The molecular surface of CD200 is shown, colored by electrostatic potential with the residues at the interaction interface bordered by a black line.\
See also [Figure S3](#app3){ref-type="sec"}.](gr3){#fig3}

![Sequence Alignment of the Extracellular Regions of the CD200R Family and CD200\
The sequences for mouse CD200R (NP_067300), mouse CD200RLa (NP_997127) and human CD200R (NP_740750) are shown in (A) and the sequences for mouse and human CD200 (accession numbers NP_034948 and EAW79672 respectively) are shown in (B). Amino acid secondary structure is based on the mouse CD200R and CD200 structures. Residues identical between the sequences are highlighted in blue. NH~2~-terminal residues determined by protein sequencing are highlighted in cyan; CD200RLa consisted of a mixture of two different NH~2~ termini differing by one amino acid starting with either Cys or Thr. The NH~2~ termini of recombinant human and mouse CD200 was not detected presumably due to the presence of cyclized glutamine (pyroglutamic acid) as predicted from peptide analysis of rat CD200 ([@bib13]). Potential N-linked glycosylation sites are shown in pink. Cys residues forming disulfide bonds are numbered below the alignment. Residues at the CD200/CD200R interface are denoted by asterisks. Cys residues forming disulfide bonds are numbered below the alignment. Residues at the mouse CD200/CD200R interface are denoted by asterisks. Single point mutations of human CD200R ([@bib24]) and mouse CD200 are highlighted according to their ability to bind human CD200 and mouse CD200R respectively; red denotes mutation results in \< 25% wild-type binding, yellow 25%--75%, and green \> 75% binding.](gr4){#fig4}

![Single Point Mutations in CD200 at the CD200/CD200R Interface Prevent CD200R Binding\
(A) Surface plasmon resonance experiment shows immobilized CD200 mutant Q7K (green line) binds soluble CD200R similarly to wild-type (WT) CD200 (blue line), whereas CD200 mutant N44A (red line) and the negative control CD4 (pink dashed line) do not bind CD200R. Injection of soluble CD200R over the immobilized proteins is represented by the solid black bar.\
(B) Single point mutation of CD200 at the crystallographic CD200/CD200R interface prevents the interaction. The molecular surface of CD200 is shown in the same orientation as in [Figure 3](#fig3){ref-type="fig"}D. Single point mutations of mouse CD200 are colored according to their ability to bind mouse CD200R. Residues colored red denote mutation results in \< 25% wild-type binding and green \> 75% binding.\
(C) Mapping of single point mutations of human CD200R ([@bib24]) onto the mouse CD200R structure delineates the CD200 binding site to the AGFCC′C″ face. Residues colored red denotes mutation resulting in \< 25% wild-type binding, yellow 25%--75% and green \> 75% binding. (B) and (C) are in the same orientation as [Figures 3](#fig3){ref-type="fig"}D and 3C, respectively.\
See also [Table S1](#app3){ref-type="sec"}.](gr5){#fig5}

![The Inability of CD200RLa to Bind CD200\
(A) The structure of CD200 (green cartoon) in complex with CD200R (orange surface) is shown. Residues differing between CD200La and CD200R are colored cyan. Additional residues of CD200RLa that differ from the CD200R sequence crystallized but that are found in other CD200R variants (from Ensembl database, <http://www.ensembl.org>) are colored white. Three residues of CD200R that differ from CD200RLa that are at or peripheral to the CD200/CD200R interface are labeled.\
(B) Left panel: transparent surface and cartoon representation of the CD200 (green) in complex with CD200R (orange); F36 and F114 are shown as sticks and colored purple. Right panel: virtual complex between CD200RLa (cyan) and CD200 (green); F36 and L114 are colored purple and the loss of the N-terminal strand from the interface is highlighted.\
(C) Surface plasmon resonance experiments show that mutation of three CD200RLa residues (N63, K66 and L114F) is required to gain CD200 binding (∼60% of wild-type). Recombinant CD200R, wild-type CD200RLa, and mutant CD200RLa were immobilized on a BIAcore chip and increasing concentrations of CD200 were injected over the proteins. A representative experiment is shown. K~D~s were calculated by nonlinear curve fitting. The number (n) of times the experiment was repeated and the standard deviation (SD) of the K~D~s calculated are given.\
For differences between the receptors, see alignment in [Figure S4](#app3){ref-type="sec"}.](gr6){#fig6}

![Topology of the CD200/CD200R Interaction at the Cell Surface\
The dimensions of the CD200/CD200R interaction are compared to other interactions thought to occur in immunologic synapses. A model of the CD47/SIRPα interaction was generated by superimposing the crystal structure of the full extracellular domain of SIRPα (Protein Data Bank ID \[PDB\] code [2wng](pdb:2wng){#intref0060}) onto the crystal structure of the V-like domain of SIRPα in complex with CD47 (PDB code [2jjs](pdb:2jjs){#intref0065}). Cartoons for the crystal structures of PD-1/PD-L1 (PBD code [3bik](pdb:3bik){#intref0070}), CD4/TCR/MHC (PDB code [3t0e](pdb:3t0e){#intref0075}), and CTLA-4/CD80 (PDB code [1i8l](pdb:1i8l){#intref0080}) are shown. The approximate dimensions of the interacting protein complexes are shown. The last observed COOH-terminal residue in each structure is represented as a sphere. The number of amino acid (aa) residues that link the protein structures to their predicted transmembrane regions are given. Observed NAG and mannose moieties are shown as pink sticks and the sites of potential N-linked glycosylation sites are shown as pink spheres.](gr7){#fig7}

![The CD200/CD200R Binding Site Is Conserved in Mammals and Some Viruses\
The ConSurf Server ([@bib3]) was used to estimate the evolutionary conservation of amino acids in CD200 and CD200R using a multiple sequence alignment of mammalian (and two viral) CD200 and CD200R orthologs (generated by Clustal W2 ([@bib29]) and the CD200/CD200R coordinates.\
(A) Left panel: conservation of CD200R amino acids in the following mammals: mouse (NP_067300.1), human (NP_620161.1), chimp (XP_001156654.1), monkey (XP_001105494.1), wolf (XP_545099.2), cow (XP_002684796.2), and rat (NP_076443.1). The view of CD200R is the same as that in [Figure 3](#fig3){ref-type="fig"}C. Centere panel: conservation of CD200 amino acids in the following mammals: mouse (NP_034948.3), human (NP_001004196.2), chimp (XP_516648.3), monkey (XP_001104031.1), wolf (XP_849283.2), cow (NP_001029792.1), and rat (NP_113706.1). The view of CD200 is the same as that in [Figure 3](#fig3){ref-type="fig"}D. Right panel: conservation of CD200 amino acids in mammals (as in center panel) and the viral orthologs K14 (AAK53415.1) and e127 (AAO45420.1) from the human herpes virus 8 (HHV8) and the rat cytomegalovirus (RCMV), respectively. The black line outlines the residues at the CD200/CD200R interface. The relative degrees of residue conservation are colored from blue for variable positions to dark pink for conserved residues.\
(B) CD200R and CD200 are rotated 180° from (A).](gr8){#fig8}

###### 

Data Collection and Refinement Statistics

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                    CD200RLa (native)                    CD200RLa (gadolinium)               CD200R                    CD200/CD200R Complex
  ------------------------------------------------------------------------------------------------- ------------------------------------ ----------------------------------- ------------------------- -------------------------
  **Data Collection Statistics**                                                                                                                                                                       

                                                                                                                                                                                                       

  Beamline                                                                                          ID23-1 (ERSF)                        I03 (diamond)                       I04 (diamond)             I04 (diamond)

  Wavelength (Å)                                                                                    0.9762                               1.7112                              0.9795                    0.9840

  Resolution limits (Å)[a](#tblfn1){ref-type="table-fn"}                                            168.02--2.5 (2.63-2.5)               137.05--3.5 (3.69-3.5)              38.84--2.08 (2.13-2.08)   86.04--3.22 (3.31-3.22)

  Space group                                                                                       *P6*~*5*~*22*                        *P6*~*5*~*22*                       *P*4~1~ 2~1~ 2            *P*4~3~ 2~1~ 2

  Unit cell dimensions (Å, °)                                                                       157.76, 157.76, 167.91 90, 90, 120   158.25, 158.25, 167.5 90, 90, 120   51.97, 51.97, 175.42      128.17, 128.17, 115.08

  90, 90, 90                                                                                        90, 90, 90                                                                                         

  Total number of observations                                                                      151,989                              93,847                              116,395                   101,278

  Unique reflections                                                                                42,242                               16,156                              15,423                    16,034

  Multiplicity[a](#tblfn1){ref-type="table-fn"}                                                     3.6 (3.5)                            5.8 (5.9)                           7.5(7.3)                  6.3 (6.6)

  Completeness (%)[a](#tblfn1){ref-type="table-fn"}                                                 98.4 (99.7)                          99.8 (99.8)                         99.8 (99.5)               99.6 (99.5)

  *Iσ* (*I*)[a](#tblfn1){ref-type="table-fn"}                                                       13.0 (2.2)                           10.9 (5.1)                          16.8 (3.1)                10.2 (2.9)

  *R*~merge~ (%)[a](#tblfn1){ref-type="table-fn"}^,^[b](#tblfn2){ref-type="table-fn"}               6.9 (49.4)                           15.4 (39.0)                         7.8 (73.8)                12.0 (68.3)

  *R*~anom~ (%)[a](#tblfn1){ref-type="table-fn"}^,^[c](#tblfn3){ref-type="table-fn"}                                                     9.0 (15.9)                                                    

  Processing programs                                                                               MOSFLM/SCALA                         XIA2/SCALA                          XIA2                      XIA2

                                                                                                                                                                                                       

  **Refinement Statistics**                                                                                                                                                                            

                                                                                                                                                                                                       

  Resolution limits (Å)                                                                             15.0--2.5 (2.56--2.5)                                                    15.0--2.08                86.04--3.22

  Number of reflections in working set                                                              39,601                                                                   14,424                    14,465

  Number of reflections in test set                                                                 2,115                                                                    758                       819

  *R*-factor of working set [a](#tblfn1){ref-type="table-fn"}^,^[d](#tblfn4){ref-type="table-fn"}   0.171 (0.248)                                                            0.198 (0.236)             0.199 (0.313)

  *R*~free~[a](#tblfn1){ref-type="table-fn"}^,^[e](#tblfn5){ref-type="table-fn"}                    0.205 (0.291)                                                            0.232 (0.270)             0.251 (0.360)

  Number of atoms\                                                                                  4,328/210/625/53                                                         1,464/42/148/11           3,035/154/27/4
  (protein/carbohydrate/water/other[f](#tblfn6){ref-type="table-fn"})                                                                                                                                  

  Residues in Ramachandran-favored region (%)                                                       98.4                                                                     97.3                      94.1

  Ramachandran outliers (%)                                                                         0.0                                                                      0.0                       0.0

  Rmsd bond lengths (Å)                                                                             0.010                                                                    0.0100                    0.007

  Rmsd bond angles (°)                                                                              1.23                                                                     1.32                      1.40

  Average *B* factors (Å^2^) (protein/carbohydrate/water/other[f](#tblfn6){ref-type="table-fn"})    45/83/55/107                                                             39/42/48/55               93/122/63/68
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Numbers in parentheses refer to the appropriate outer shell.

*R*~merge~ = 100 x (Σ~hkl~ Σ~i~\|*I(hkl;i)* − \< *I(hkl)* \> \|/Σ~hkl~ Σ~i~*I(hkl;i))*, where *I(hkl;i)* is the intensity of an individual measurement of a reflection and \< *I(hkl)* \> is the average intensity of that reflection.

*R*~anom~ = 100 x Σ \|Mn(I+) − Mn(I−)\|/Σ (Mn(I+) + Mn(I−)) where R~anom~ is the ratio between the mean intensity difference between Bijvoet pairs (\|Mn(I+) − Mn(I−)\|) and the mean intensity of Bijvoet pairs (Mn(I+) + Mn(I−).

*R*~factor~ = (Σ~hkl~\|\|*F*~obs~\| − \|*F*~calc~\|\|/Σ~hkl~ \|*F*~obs~\|), where \|*F*~obs~\| and \|*F*~calc~\| are the observed and calculated structure facture amplitudes.

*R*~free~ equals the *R*-factor of test set (5% of the data removed prior to refinement).

Other atoms include polyethylene glycol, sulfate, glycerol, acetate.

###### 

Experimental Phasing Statistics for CD200RLa

  Phasing Power   SIR                                             SAD                                            
  --------------- ----------------------------------------------- ---------------------------------------------- -------
  78.8--11.08 Å   5.174                                           3.221                                          1.508
  11.08--7.87 Å   3.400                                           2.192                                          1.172
  7.87--6.44 Å    2.213                                           1.487                                          0.769
  6.44--5.58 Å    1.457                                           0.990                                          0.505
  Overall         0.918                                           1.064                                          0.359
                  FOM Acentric[a](#tblfn7){ref-type="table-fn"}   FOM Centric[a](#tblfn7){ref-type="table-fn"}   
  78.8--11.08 Å   0.83238                                         0.71582                                        
  11.08--7.87 Å   0.71049                                         0.65144                                        
  7.87--6.44 Å    0.55196                                         0.54371                                        
  Overall         0.07967                                         0.15751                                        

The overall figure of merit (FOM) is before density modification. After solvent flattening, the FOM is 0.894. Only resolution bins with phasing power \>1 or FOM \>0.5 are shown.
